Brief Intervention for OCD Fears

Phase 4

Withdrawn

• Conditions: Obsessive-compulsive Disorder
• Interventions: Drug: Propanolol; Drug: Placebo

• Registration Number: NCT02790710
• Lead Sponsor: New York State Psychiatric Institute

Brief Summary

The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.

Detailed Description

Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear reactivation procedure. Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention

Study Timeline

• Study First Submitted: 2016-05-26
• Study Start: 2016-06
• Study First Submitted QC: 2016-06-03
• Study First Posted: 2016-06-06
• Status Verified: 2023-04
• Primary Completion: 2023-04
• Study Completion: 2023-04
• Last Update Submitted: 2023-04-12
• Last Update Posted: 2023-04-18

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Principal Diagnosis of Obsessive-Compulsive Disorder

Exclusion Criteria

• History of other serious psychiatric disorder
• Current Major Depressive Disorder
• Women who are pregnant or nursing
• Current use of psychiatric medication
• Persons planning to start another treatment during the study period
• Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Propanolol	Propanolol	Propranolol 40 mg capsule, given once after fear reactivation procedure
Placebo capsule	Placebo	Placebo capsule, given once after fear reactivation procedure

Primary Outcome Measures

Name	Time	Method
Yale Brown Obsessive-Compulsive Scale	2 weeks	Total score on this Clinician-administered measure of OCD symptoms

Secondary Outcome Measures

Name	Time	Method
Behavioral Avoidance Task	2 weeks	Total number of steps completed (0-5) on this task assessing avoidance of OCD triggers

Trial Locations

Locations (1)

New York State Psychiatric Institute; 🇺🇸 New York, New York, United States